die('
Site is under construction
Dear site users
Site is under construction.
The site will be ready in less than 24 hours.
We are sorry for the inconvenience.
www.yektaweb.com
');
Reports of Biochemistry and Molecular Biology
rbmb.net
Basic Sciences
http://rbmb.net
1
admin
2322-3480
2322-3480
10.61882/rbmb
en
jalali
1399
3
1
gregorian
2020
6
1
9
2
online
1
fulltext
en
Examining the Frequency of the JAK2 (V617F) Mutation in Patients with Myeloproliferative Diseases in North Eastern Iran and the Effect of Treatment Intervention
بیوشیمی
Biochemistry
مقالات اصلی
Original Article
<div style="text-align: justify;"><strong><em>Background: </em></strong>Janus kinase 2 (<em>JAK2</em>) is a tyrosine kinase located in the cytoplasm that plays a critical role in the signal transduction of cytokines and growth hormones. The conversion of valine to phenylalanine at the polypeptide position 617 results in the <em>JAK2</em> (V617F) mutation, which often found in patients with myeloproliferative neoplasms (MPNs). As a result of this mutation, <em>JAK2</em> is constitutively activated leading to uncontrolled cell growth. The present study aimed to investigate the frequency and relationship of the <em>JAK2</em> (V617F) mutation in a population of patients with MPNs in Iran.<br>
<br>
<strong><em>Methods:</em></strong> A total of 213 patients with myeloproliferative diseases (MPDs), were included in the study. Real-time PCR was used to detect the presence of the <em>JAK2 </em>(V617F) mutation in the genomic DNA isolated from patient peripheral blood samples.<br>
<br>
<strong><em>Results:</em></strong> Of the 213 patients with MPDs, approximately 60 (28%) patients were positive for the <em>JAK2</em> (V617F) mutation. Polycythemia Vera (PV, 42.11%) was the most common MPD, followed by Essential Thrombocythemia (ET, 29.82%), Primary Myelofibrosis (MF, 12.28%), and Chronic Myeloid Leukemia (CML, 10.5%). A significant relationship between all types of MPDs and the clinical course (<em>p</em>< 0.05) was observed. The relationship between age and gender among all types of MPD disease was not significant (<em>p</em>> 0.05).<br>
<br>
<strong><em>Conclusions:</em></strong> Of the examined cohort in North Eastern Iran, 28% of the patients with MPNs were found to have the <em>JAK2</em> (V617F) mutation which determining the presence of the <em>JAK2</em> (V617F) mutation helps to decide the correct form of treatment.</div>
AK2 (V617F), JAK-STAT pathway, MPD Real-Time PCR, Treatment
188
192
http://rbmb.net/browse.php?a_code=A-10-353-1&slc_lang=en&sid=1
Mojila
Nasseri
100319475328460017590
100319475328460017590
No
Department of Biochemistry, Payamenoor University, Tehran, Iran
Fatemeh
Keyfi
100319475328460017591
100319475328460017591
No
Department of Medical Laboratory Sciences, Varastegan Institute for Medical Sciences, Mashhad, Iran & Pardis Clinical and Genetics Laboratory, Mashhad, Iran
Raheleh
Rahbarian
100319475328460017592
100319475328460017592
No
Department of Biochemistry, Payamenoor university, Tehran, Iran
Majid
Rajabian
100319475328460017593
100319475328460017593
No
Department of biology, Payamenoor University, Tehran, Iran
Mohammad Reza
Abbaszadegan
abbaszadeganmr@mums.ac.ir
100319475328460017594
100319475328460017594
Yes
Pardis Clinical and Genetics Laboratory, Mashhad, Iran & Division of Human Genetics, Immunology Research Center, Avicenna Research Institute, MUMS, Mashhad, Iran